Oslo - Delayed Quote NOK
Zelluna ASA (ZLNA.OL)
13.75
-0.15
(-1.06%)
At close: May 16 at 4:27:17 PM GMT+2
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Anders Tuv | Co-Founder & Chairman | -- | -- | -- |
| Mr. Namir Hassan Ph.D. | Chief Executive Officer | -- | -- | -- |
| Mr. Hans Ivar Robinson | Co-Founder & Non Executive Director | -- | -- | 1967 |
| Mr. Hans Vassgard Eid | Chief Financial Officer | -- | -- | -- |
| Mr. Anders Holm Ph.D. | Chief Operating Officer & Head of Business Development | -- | -- | -- |
| Ms. Luise Weigand Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Ms. Julia Ino Ph.D. | Head of Project Management | -- | -- | -- |
| Ms. Emilie Gauthy Ph.D. | Head of Chemistry, Manufacturing & Controls | -- | -- | -- |
| Mr. Oivind Foss Ph.D. | Head of Clinical Operations | -- | -- | -- |
Zelluna ASA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 27
Description
Zelluna ASA develops T-cell receptor (TCR) cellular immunotherapy products for the treatment of solid cancers. The company was founded in 2016 and is based in Oslo, Norway.
Corporate Governance
Zelluna ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 8, 2025 at 5:00 AM UTC
Zelluna ASA Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
ONCIN.OL Oncoinvent ASA
1.6060
+1.01%
LYTIX.OL Lytix Biopharma AS
7.60
-1.30%
BGBIO.OL BerGenBio ASA
1.7500
+2.58%
ONCO.ST Oncopeptides AB (publ)
2.0000
+2.56%
VRCA Verrica Pharmaceuticals Inc.
0.6623
+3.19%
TVTX Travere Therapeutics, Inc.
16.80
-20.57%
ABCL AbCellera Biologics Inc.
2.0300
+0.50%
VXRT Vaxart, Inc.
0.5051
+18.99%
VKTX Viking Therapeutics, Inc.
28.43
+3.76%
MRNA Moderna, Inc.
24.86
+5.12%